as 11-12-2024 4:00pm EST
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
Upcoming Earnings Alert:
Get ready for potential market movements as Enliven Therapeutics Inc. ELVN prepares to release earnings report on 19 Nov 2024.
Founded: | 2016 | Country: | United States |
Employees: | N/A | City: | BOULDER |
Market Cap: | 1.3B | IPO Year: | 2020 |
Target Price: | $34.75 | AVG Volume (30 days): | 232.2K |
Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.92 | EPS Growth: | N/A |
52 Week Low/High: | $9.80 - $30.03 | Next Earning Date: | 11-19-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | Oct 18 '24 | Sell | $30.00 | 847 | $25,412.54 | 1,015,188 | |
Collins Helen Louise | ELVN | CHIEF MEDICAL OFFICER | Oct 18 '24 | Sell | $30.00 | 816 | $24,482.45 | 0 | |
Kintz Samuel | ELVN | PRESIDENT AND CEO | Oct 18 '24 | Sell | $30.00 | 924 | $27,722.68 | 1,002,892 | |
Heyman Richard A. | ELVN | Director | Oct 15 '24 | Sell | $27.67 | 1,270 | $35,143.31 | 124,490 | |
Ballal Rahul D. | ELVN | Director | Oct 8 '24 | Sell | $28.17 | 10,420 | $293,557.45 | 22,341 | |
Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | Oct 4 '24 | Sell | $27.56 | 10,229 | $281,664.00 | 1,015,188 | |
Hohl Benjamin | ELVN | CHIEF FINANCIAL OFFICER | Oct 4 '24 | Sell | $27.51 | 11,488 | $316,014.07 | 0 | |
Kintz Samuel | ELVN | PRESIDENT AND CEO | Oct 4 '24 | Sell | $27.51 | 14,936 | $410,866.94 | 1,002,892 | |
Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | Oct 1 '24 | Sell | $27.54 | 527 | $14,512.10 | 1,015,188 | |
Heyman Richard A. | ELVN | Director | Oct 1 '24 | Sell | $27.54 | 518 | $14,264.32 | 124,490 |
ELVN Breaking Stock News: Dive into ELVN Ticker-Specific Updates for Smart Investing
PR Newswire
5 days ago
MT Newswires
13 days ago
Yahoo Finance Video
25 days ago
Clinical Trials Arena
a month ago
GlobeNewswire
2 months ago
Zacks
2 months ago
GlobeNewswire
2 months ago
Benzinga
2 months ago
The information presented on this page, "ELVN Enliven Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.